2017 : Academy of Managed Care Pharmacy

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

 

2018

 

2017

 

2016

 

2015

 

2014

 

December

12/28/2017

AMCP Submits Comments to the FDA on Potential Areas of Focus for the Opioid Policy Steering Committee   

12/15/2017

AMCP Provides Response to Request for Information on Value Based Contracting from Diabetes Caucus Co-Chairs Diana DeGette (D-CO) and Tom Reed (R-NY)   

12/8/2017

AMCP Submits Comments to the FTC on Solutions and Strategies to Improve Generic Competition in the Marketplace   

November

11/27/2017

AMCP Comments on HHS Notice of Benefit and Payment Parameters for 2019   

11/20/2017

AMCP Comments to FDA on Direct to Consumer Advertising Provisions   

11/20/2017

AMCP Submits Comments to CMMI on Recommendations to Transform Medicare and Medicaid Programs   

October

10/25/2017

AMCP joins pharmacy associations in statement for the record on House Energy & Commerce Committee opioid hearing advocating for pharmacists to be eligible for DATA waivers to provide MAT   

10/2/2017

AMCP Provides Input on Texas Board of Pharmacy Strategic Plan for 2019-2023   

September

9/28/2017

AMCP Submits Comments on the Healthy People 2030 Draft Framework Supporting Foundational Principle #2   

9/26/2017

AMCP submits comments to Arkansas State Board of Pharmacy regarding biosimilars supporting interchangeability provisions and seeking further clarification on definitions   

9/18/2017

AMCP submits comments to FDA on Hatch-Waxman reform advocating for the prohibition of strategies that unnecessarily delay the entry of generic medications into the marketplace for reasons other than safety and efficacy   

9/11/2017

AMCP submits comments on Draft CY2018 Medicare Part B Physician Fee Schedule urging CMS to critically evaluate coding & reimbursement options under Part B to ensure patient access and affordability of biologics and biosimilars, require documentation of Part B drug claims using NDCs, and categorize biosimilars as applicable drugs under Part D   

9/8/2017

Partnership to Amend 42 CFR Part 2 adds another member, increasing membership to 37.    

August

8/29/2017

AMCP Submits Comments on ICER’s Potential Topics for Review in 2018   

8/24/2017

AMCP Submits Comments to ISPOR on Initiative on US Value Assessment Frameworks: Draft Special Task Force Report   

8/21/2017

AMCP submits comments to CMS on the CY 2018 Updates to the Quality Payment Program.   

July

7/28/2017

AMCP along with other members of the Partnership to Amend 42 CFR Part 2 applauds the introduction of H.R. 3545 the “Overdose Prevention and Patient Safety Act”. The Act has bipartisan support and will protect the confidentiality of substance use disorder patient records.   

7/27/2017

AMCP sends letter to the House Judiciary Subcommittee on Commercial & Antitrust Law in support of H.R. 2212, the CREATES Act, bipartisan legislation designed to increase patient access to generic and biosimilar medications.   

7/18/2017

Friends of NQF urge Congress to continue Medicare funding for the NQF and its work to advance our national commitment to safer, more effective care. This letter is signed by more than 100 organizations supporting reauthorization of federal funding for NQF's critical work.   

7/10/2017

AMCP joins 20+ organizations in joint letter of support for H.R. 2026 –The Pharmaceutical Information Exchange (PIE) Act of 2017  

June

6/2/2017

AMCP submits comments to ICER on draft evidence report for abuse deterrent formulations of opioids. 

6/1/2017

AMCP sends a letter to the New York Senate Higher Education Committee expressing concerns with specific provisions of Senate Bill 4788, regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.   

May

5/30/2017

AMCP sends a letter to the Michigan House Health Policy Committee expressing concerns with specific provisions of House Bill 4472, regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.   

5/26/2017

AMCP Comments on ISPOR Draft Special Task Force Report on Health Economics Approach to Value Assessment Frameworks.  

5/25/2017

AMCP Delivers Remarks on Biosimilars Position at FDA Oncologic Drug Advisory Committee Meeting.  

5/19/2017

AMCP submits comments to the FDA on the biosimilar interchangeability draft guidance seeking additional clarity prior to finalization.  

5/18/2017

AMCP Joins 10 Organizations in Joint Comment Letter to the FDA on Draft Interchangeability Guidance.  

5/15/2017

AMCP submits comments to the Washington Department of Labor & Industries supporting a proposed rule that would require the dispensing of an interchangeable biological product when available unless the provider specifically indicates that substitution is not permitted for the Washington Prescription Drug Program. 

AMCP sends a letter to Connecticut House leadership expressing concerns with specific provisions of Substitute Bill No. 7118 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.  

 5/11/2017

AMCP sends a letter to Tennessee Governor Bill Haslam urging him to sign House Bill No. 628, which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program.    

5/4/2017

AMCP submits comments to Tennessee House leadership expressing strong support for House Bill No. 628 which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program.   

AMCP submits comments to Tennessee Senate leadership expressing strong support for Senate Bill No. 398 which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program.  

5/3/2017

AMCP submits comments to PQA on three new measures under consideration for endorsement, advocating for measures with a focus on outcomes, consideration for clinical appropriateness of medications, and avoidance of duplication of measures. 

April

4/27/2017

AMCP joins 17 other health care organizations and consumer groups in support of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2017 – H.R. 2212 and S. 974. This bipartisan legislation is designed to increase access to generic and biosimilar medications. 

4/24/2017

AMCP submits comments to CMS advocating for transformation and modernization of the Medicare Part D program to best meet the individual health care needs of Medicare beneficiaries. 

4/19/2017

AMCP joins 30+ organizations representing population health decision makers, biopharmaceutical and medical device manufacturers, patient advocacy groups, health care providers, health economists, and others in joint comments to the FDA advocating for timelier and more proactive sharing of preapproval and post-approval health care economic information (HCEI) between biopharmaceutical and medical device manufacturers and population health decision makers. 

AMCP submits comments to FDA advocating for clarification of FDAMA Section 114 and the creation of a safe harbor for preapproval information exchange.   

4/13/2017

AMCP submits comments to the Alaska House Health & Social Services Committee expressing concerns with specific provisions of Senate Bill No. 32 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.4/6/2017

AMCP joins 17 other health care organizations and consumer groups in support of the Fair Access for Safe and Timely “FAST” Generics Act of 2017 – H.R. 2051. This bipartisan legislation is designed to increase access to generic and biosimilar medications.  

4/3/2017 

AMCP submits comments on ICER’s Proposed Updates to the Value Assessment Framework to further enhance the utility and relevance of the value assessment framework to managed care pharmacy. 

March

3/23/2017

AMCP submits comments to CMS on the average length and cost to mail the Medicare Part D MTM Standardized Format, continuing to advocate for modernization of the standardized format.  

3/20/2017

AMCP submits comments to Maryland House leadership expressing concerns with specific provisions of House Bill 1273 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.  

AMCP submits comments to the Maryland House Health and Government Operations Committee expressing concerns with specific provisions of Senate Bill 997 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.  

3/9/2017

AMCP submits comments to the Arkansas House Public Health, Welfare and Labor Committee expressing concerns with specific provisions of House Bill 1204 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists. 

3/3/2017

AMCP Submits Comments to CMS on 2018 Draft Call Letter.
 

February

3/3/2017

The Partnership for Safe Medicines (PSM), a group AMCP is part of, sent a letter to all members of Congress urging them to continue protecting Americans and stand against efforts that would allow substandard and even dangerous counterfeit medicines to flow freely across U.S. borders and into the hands of the American people.  

2/27/2017

AMCP submits comments to the Vermont Senate Health and Welfare Committee expressing concerns with specific provisions of Senate Bill 92 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.   

AMCP submits comments to the Alaska Senate Labor and Commerce Committee expressing concerns with specific provisions of Senate Bill No. 32 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.   

AMCP submits comments to the Alabama House Health Committee expressing concerns with specific provisions of House Bill 82 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.   

2/16/2017

AMCP continues to work with 27 other organizations in efforts to urge Congress to align 42 CFR part 2 with HIPPA, essential to providing whole person care.   

AMCP submits comments to the Nebraska Senate Health and Human Services Committee expressing concerns with specific provisions of LB 481 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.  

January

1/17/2017

The Partnership to Amend 42 CFR Part 2, a coalition AMCP is part of, issues a comment on the SAMHSA Final Rule and urges Congress to take the next steps in modernizing 42 CFR Part 2.  

• Letters, Statements and Analysis 

  Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and th

  Read More » 
   
• Letters, Statements and Analysis - 2013 

  » 2011   » 2010   » 2009   » 2008   » 2007   » 2006   » AMCP comments to CMS on adoption of NCPDP SCRIPT version 10.6 for electronic prescribing in the Medicare Prescription Drug Program 08/12/2010 » AMCP comments to the Office of Co

  Read More » 
   
• Letters, Statements and Analysis - 2014 

  » 2011   » 2010   » 2009   » 2008   » 2007   » 2006   » AMCP comments to CMS on adoption of NCPDP SCRIPT version 10.6 for electronic prescribing in the Medicare Prescription Drug Program 08/12/2010 » AMCP comments to the Office of Co

  Read More » 
   
• Letters, Statements and Analysis - 2015 

  » 2011   » 2010   » 2009   » 2008   » 2007   » 2006   » AMCP comments to CMS on adoption of NCPDP SCRIPT version 10.6 for electronic prescribing in the Medicare Prescription Drug Program 08/12/2010 » AMCP comments to the Office of Co

  Read More » 
   
• Letters, Statements and Analysis - 2016 

  Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and th

  Read More » 
   
• Letters, Statements and Analysis - 2017 

  Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and th

  Read More » 
   
• Letters, Statements and Analysis- 2018 

  Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and th

  Read More »